IMR Press / CEOG / Special Issues / 1639039557323

Current Research on Endometrial and Ovarian Cancers

Submission deadline: 30 June 2022
Special Issue Editors
Federico Ferrari, MD, PhD
Department of Obstetrics and Gynecology, Spedali Civili Brescia, Brescia, Italy
Interests: Minimally invasive surgery; Enhanced recovery after surgery (ERAS); Endometrial cancer; Ovarian cancer; Cervical cancer; Vulvar cancer
Special Issue Information

Dear Colleagues,

The cornerstone of treatment for endometrial cancer (EC) is surgery, which is important not only for staging purposes but also the appropriate tailoring of adjuvant treatment modalities. In the last year, we assisted in a paradigm shift of the benefits of lymph nodal staging, expanding from classic high-risk patients to include low risk patients. In fact, EC is no longer considered a dualistic disease (type I and type II disease), but one of four molecular subgroups that have been identified, overcoming historical prognostic factors and classification: POLE ultra-mutated, mismatch repair-deficient, p53 mutant and EC lacking any of these alterations, referred to as NSMP. While the impact of this molecular classification is evident, further research is necessary to provide new molecular-based standards for surgical and medical treatment of these patients.
Conversely, ovarian cancer (OC) is currently very difficult to cure as it is typically diagnosed only at an advanced stage. Conventional treatment of OC includes aggressive debulking surgery and adjuvant chemotherapy, even though this approach rarely can permanently halt the progression of the disease. Introduction of PARP inhibitor ameliorates the prognosis of this disease in selected patients, even though development of targeted therapy is poor compared to other solid tumors. In parallel to medical treatment, current findings have confirmed that surgical approach with no residual disease, including in cases of recurrence, can play an appreciable role in survival trends. Lastly, quality of life is one of the crucial aims that must be considered early by clinicians in the global treatment of these patients. Future research is based on a complicated intersection of these components, namely, surgical approach, targeted therapy and quality of life that could together finally improve the prognosis of OC patients.

Dr. Federico Ferrari

Guest Editor

Endometrial cancer
Molecular classification
Ovarian cancer
Target therapy
Minimally invasive surgery
Debulking surgery
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (1 Paper)
Open Access Original Research
TCOF1 is Identified to be an Unfavorable Biomarker and is Associated with Molecular Classification in Endometrial Cancer
Caiqiu Xu, Qinghai Wang, Yilin Zhang, Qirun Guo, ... Suiqun Guo
Clin. Exp. Obstet. Gynecol. 2022, 49(5), 112;
(This article belongs to the Special Issue Current Research on Endometrial and Ovarian Cancers)
Back to top